NLS Pharmaceutics Schedules Shareholder Meetings for September 18
Ticker: NCEL · Form: 6-K · Filed: Aug 26, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Aug 26, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing
TL;DR
NLS Pharma calling shareholder meetings Sept 18, record date Aug 23. Vote matters!
AI Summary
NLS Pharmaceutics Ltd. announced two Extraordinary Shareholders' Meetings to be held on September 18, 2024. Shareholders of record as of August 23, 2024, are eligible to vote. The filing is a Report of Foreign Private Issuer for the month of August 2024.
Why It Matters
The meetings are crucial for NLS Pharmaceutics to potentially make significant corporate decisions that could impact its future direction and shareholder value.
Risk Assessment
Risk Level: medium — Shareholder meetings can lead to significant corporate changes, which inherently carry risk for investors.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- September 18, 2024 (date) — Date of Extraordinary Shareholders' Meetings
- August 23, 2024 (date) — Record date for shareholders eligible to vote
FAQ
What is the purpose of the Extraordinary Shareholders' Meetings?
The filing states that the meetings are to address matters requiring shareholder approval, though specific agenda items are not detailed in this excerpt.
Who is eligible to vote at the meetings?
Shareholders of record who hold common shares of NLS Pharmaceutics Ltd. at the close of business on August 23, 2024, are entitled to vote.
When are the Extraordinary Shareholders' Meetings scheduled to take place?
The meetings are scheduled to be held on September 18, 2024.
What type of filing is this for NLS Pharmaceutics Ltd.?
This is a Form 6-K, a Report of Foreign Private Issuer, for the month of August 2024.
Where is NLS Pharmaceutics Ltd. headquartered?
NLS Pharmaceutics Ltd. is headquartered in Zurich, Switzerland.
Filing Stats: 305 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-08-26 16:40:22
Filing Documents
- ea0212353-6k_nlspharma.htm (6-K) — 12KB
- ea021235301ex99-1_nlspharma.htm (EX-99.1) — 301KB
- ex99-1_001.jpg (GRAPHIC) — 107KB
- ex99-1_002.jpg (GRAPHIC) — 218KB
- ex99-1_003.jpg (GRAPHIC) — 194KB
- ex99-1_004.jpg (GRAPHIC) — 211KB
- 0001213900-24-072621.txt ( ) — 1319KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: August 26, 2024 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 3